


Amendment to the claims.


Please amend claims 1, 15, 28 and 30, cancel claims 16-17, 21-23, 26-27 and 29 without prejudice and add new claims 34 and 35 as set forth below.

Listing of Claims. This listing replaces any previous listing.

1 (Currently Amended). A purified polypeptide comprising the amino acid sequence of SEQ ID NO: 4; wherein at least one of the seven variable positions of SEQ ID NO: 4 has an amino acid residue that differs from that of the corresponding wild-type Hdm2(17-125) amino acid sequence (SEQ ID NO: 2); wherein said polypeptide is soluble at a 34 mg/ml concentration in 25 mM Hepes-potassium hydroxide, pH 7.5, 0.15M potassium chloride, 1 mM EDTA, 0.03% sodium azide and 5 mM DTT buffer; and wherein said polypeptide is capable of binding a member selected from the group consisting of p53,




and




2 (Previously presented). The polypeptide according to claim 1, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12.

3-13 (Cancelled).

14 (Original). A compound selected from the group consisting of



and




15 (Currently Amended). A polypeptide-compound complex comprising the compound according to claim 14 and a polypeptide complexed to it, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 4, wherein at least one of the seven variable positions of SEQ ID NO: 4 has an amino acid residue that differs from that of the corresponding wild-type Hdm2(17-125) amino acid sequence (SEQ ID NO: 2); and wherein said polypeptide is soluble at a 34 mg/ml concentration in 25

1 mM Hepes-potassium hydroxide, pH 7.5, 0.15M potassium chloride, 1 mM EDTA, 0.03% sodium azide and 5 mM DTT buffer.

16 -27 (Cancelled) .


28 (Currently Amended). A crystal comprising a complex between a polypeptide having the amino acid sequence of SEQ ID NO: 10 and



wherein said polypeptide crystal is characterized by structure coordinates of Table 3 or Table 4 , in space group P2₁2₁2₁ and comprises unit cell dimensions a=37.999 Å, b=45.333 Å, c=63.999 Å, where α=β=γ=90°.

29 (Cancelled) .

30 (Currently Amended). The A crystal according to claim 28 comprising a complex between a polypeptide having the amino acid sequence of SEQ ID NO: 6 and



wherein said crystal characterized by the structural coordinates set forth in Table 4 is in space group $P2_12_12_1$ and comprises unit cell dimensions $a=41.1\text{ \AA}$, $b=42.7\text{ \AA}$, $c=53.777\text{ \AA}$, where $\alpha=\beta=\gamma=90^\circ$.

31-33 (Cancelled).

34 (New). The crystal of claim 28 wherein the complex in said crystal is characterized by structural coordinates set forth in Table 3.

35 (New). The crystal of claim 30 wherein the complex in said crystal is characterized by structural coordinates set forth in Table 4.